Bacil Pharma Ltd — Important, 09-07-2026: Company Update

Bacil Pharma's board has approved a Rights Issue to raise up to ₹50 Cr, aiming to bolster its financial position. To facilitate this and future equity plans, the authorized share capital will increase by ₹45 Cr to a total of ₹65 Cr, pending shareholder approval. The company has already appointed key intermediaries and formed a committee for the Rights Issue. Additionally, two independent directors have resigned. These decisions highlight Bacil Pharma's active steps toward capital expansion and strategic funding.